Is Alnylam Pharmaceuticals, Inc. (ALNY) a Good Choice in Biotechnology Friday?

Friday, September 23, 2022 03:43 PM | InvestorsObserver Analysts

Mentioned in this article

Is Alnylam Pharmaceuticals, Inc. (ALNY) a Good Choice in Biotechnology Friday?

Alnylam Pharmaceuticals, Inc. (ALNY) is around the top of the Biotechnology industry according to InvestorsObserver. ALNY received an overall rating of 66, which means that it scores higher than 66 percent of all stocks. Alnylam Pharmaceuticals, Inc. also achieved a score of 77 in the Biotechnology industry, putting it above 77 percent of Biotechnology stocks. Biotechnology is ranked 19 out of the 148 industries.

ALNY has an Overall Score of 66. Find out what this means to you and get the rest of the rankings on ALNY!

See Full ALNY Report

What do These Ratings Mean?

Trying to find the best stocks can be a daunting task. There are a wide variety of ways to analyze stocks in order to determine which ones are performing the strongest. InvestorsObserver makes the entire process easier by using percentile rankings that allows you to easily find the stocks who have the strongest evaluations by analysts. Our proprietary scoring system captures technical factors, fundamental analysis and the opinions of analysts on Wall Street. This makes InvestorsObserver’s overall rating a great way to get started, regardless of your investing style. Percentile-ranked scores are also easy to understand. A score of 100 is the top and a 0 is the bottom. There’s no need to try to remember what is “good” for a bunch of complicated ratios, just pay attention to which numbers are the highest.

What's Happening With Alnylam Pharmaceuticals, Inc. Stock Today?

Alnylam Pharmaceuticals, Inc. (ALNY) stock is trading at $201.36 as of 3:43 PM on Friday, Sep 23, a drop of -$1.35, or -0.67% from the previous closing price of $202.71. The stock has traded between $198.41 and $203.91 so far today. Volume today is below average. So far 364,495 shares have traded compared to average volume of 984,850 shares. Click Here to get the full Stock Report for Alnylam Pharmaceuticals, Inc. stock.